Skip to main content
Top
Published in: Neurology and Therapy 2/2020

Open Access 01-12-2020 | Alzheimer's Disease | Review

A Narrative Review of the Role of Transthyretin in Health and Disease

Authors: Marcia Almeida Liz, Teresa Coelho, Vittorio Bellotti, Maria Isabel Fernandez-Arias, Pablo Mallaina, Laura Obici

Published in: Neurology and Therapy | Issue 2/2020

Login to get access

Abstract

Transthyretin (TTR) is a tetrameric transport protein highly conserved through vertebrate evolution and synthesized in the liver, choroid plexus, and retinal pigment epithelium. TTR transports the thyroid hormone thyroxine and the retinol-binding protein (RBP) bound to retinol (vitamin A). Mutations in TTR are associated with inherited transthyretin amyloidosis (ATTRv), a progressive, debilitating disease that is ultimately fatal and is characterized by misfolding of TTR and aggregation as amyloid fibrils, predominantly leading to cardiomyopathy or polyneuropathy depending on the particular TTR mutation. Transthyretin amyloid cardiomyopathy can also occur as an age-related disease caused by misfolding of wild-type TTR. Apart from its transport role, little is known about possible additional physiological functions of TTR. Evidence from animal model systems in which TTR has been disrupted via gene knockout is adding to our cumulative understanding of TTR function. There is growing evidence that TTR may have a role in neuroprotection and promotion of neurite outgrowth in response to injury. Here, we review the literature describing potential roles of TTR in neurobiology and in the pathophysiology of diseases other than ATTR amyloidosis. A greater understanding of these processes may also contribute to further clarification of the pathology of ATTR and the effects of potential therapies for TTR-related conditions.
Literature
1.
go back to reference Li X, Buxbaum JN. Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener. 2011;6:79. Li X, Buxbaum JN. Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener. 2011;6:79.
2.
go back to reference Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75:408–27. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75:408–27.
3.
go back to reference Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398–408. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398–408.
4.
go back to reference Marcoux J, Mangione PP, Porcari R, et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med. 2015;7:1337–499. Marcoux J, Mangione PP, Porcari R, et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med. 2015;7:1337–499.
5.
go back to reference Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59:1771–6. Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59:1771–6.
6.
go back to reference Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22:171–4. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22:171–4.
7.
go back to reference Svendsen IH, Steensgaard-Hansen F, Nordvag BY. A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Eur Heart J. 1998;19:782–9. Svendsen IH, Steensgaard-Hansen F, Nordvag BY. A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Eur Heart J. 1998;19:782–9.
8.
go back to reference Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33:1120–7. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33:1120–7.
9.
go back to reference Almeida MR, Hesse A, Steinmetz A, et al. Transthyretin Leu 68 in a form of cardiac amyloidosis. Basic Res Cardiol. 1991;86:567–71. Almeida MR, Hesse A, Steinmetz A, et al. Transthyretin Leu 68 in a form of cardiac amyloidosis. Basic Res Cardiol. 1991;86:567–71.
10.
go back to reference Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97.
11.
go back to reference Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21:282–92. Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21:282–92.
12.
go back to reference Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–54. Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–54.
13.
go back to reference Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.
14.
go back to reference Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.
15.
go back to reference Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802–14. Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802–14.
16.
go back to reference Coelho T, Maia LF, da Silva MA, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92. Coelho T, Maia LF, da Silva MA, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92.
17.
go back to reference Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–166. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–166.
18.
go back to reference Raz A, Goodman DS. The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem. 1969;244:3230–7. Raz A, Goodman DS. The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem. 1969;244:3230–7.
19.
go back to reference Power DM, Elias NP, Richardson SJ, Mendes J, Soares CM, Santos CR. Evolution of the thyroid hormone-binding protein, transthyretin. Gen Compr Endocrinol. 2000;119:241–55. Power DM, Elias NP, Richardson SJ, Mendes J, Soares CM, Santos CR. Evolution of the thyroid hormone-binding protein, transthyretin. Gen Compr Endocrinol. 2000;119:241–55.
20.
go back to reference Zanotti G, Folli C, Cendron L, et al. Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein. FEBS J. 2008;275:5841–54. Zanotti G, Folli C, Cendron L, et al. Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein. FEBS J. 2008;275:5841–54.
21.
go back to reference Santos CR, Anjos L, Power DM. Transthyretin in fish: state of the art. Clin Chem Lab Med. 2002;40:1244–9. Santos CR, Anjos L, Power DM. Transthyretin in fish: state of the art. Clin Chem Lab Med. 2002;40:1244–9.
22.
go back to reference Eneqvist T, Lundberg E, Karlsson A, et al. High resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxine. J Biol Chem. 2004;279:26411–6. Eneqvist T, Lundberg E, Karlsson A, et al. High resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxine. J Biol Chem. 2004;279:26411–6.
23.
go back to reference Episkopou V, Maeda S, Nishiguchi S, et al. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA. 1993;90:2375–9. Episkopou V, Maeda S, Nishiguchi S, et al. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA. 1993;90:2375–9.
24.
go back to reference Palha JA, Hays MT, de Escobar MG, Episkopou V, Gottesman ME, Saraiva MJ. Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. Am J Physiol. 1997;272:E485–E493493. Palha JA, Hays MT, de Escobar MG, Episkopou V, Gottesman ME, Saraiva MJ. Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. Am J Physiol. 1997;272:E485–E493493.
25.
go back to reference Wolf G. Retinol transport and metabolism in transthyretin-"knockout" mice. Nutr Rev. 1995;53:98–9. Wolf G. Retinol transport and metabolism in transthyretin-"knockout" mice. Nutr Rev. 1995;53:98–9.
26.
go back to reference Fleming CE, Saraiva MJ, Sousa MM. Transthyretin enhances nerve regeneration. J Neurochem. 2007;103:831–9. Fleming CE, Saraiva MJ, Sousa MM. Transthyretin enhances nerve regeneration. J Neurochem. 2007;103:831–9.
27.
go back to reference Fleming CE, Mar FM, Franquinho F, Saraiva MJ, Sousa MM. Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci. 2009;29:3220–322. Fleming CE, Mar FM, Franquinho F, Saraiva MJ, Sousa MM. Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci. 2009;29:3220–322.
28.
go back to reference Sousa JC, Marques F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA. Transthyretin influences spatial reference memory. Neurobiol Learn Mem. 2007;88:381–5. Sousa JC, Marques F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA. Transthyretin influences spatial reference memory. Neurobiol Learn Mem. 2007;88:381–5.
29.
go back to reference Brouillette J, Quirion R. Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging. 2008;29:1721–32. Brouillette J, Quirion R. Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging. 2008;29:1721–32.
30.
go back to reference Sousa JC, Grandela C, Fernandez-Ruiz J, et al. Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem. 2004;88:1052–8. Sousa JC, Grandela C, Fernandez-Ruiz J, et al. Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem. 2004;88:1052–8.
31.
go back to reference Buxbaum JN, Roberts AJ, Adame A, Masliah E. Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects. Neuroscience. 2014;275:352–64. Buxbaum JN, Roberts AJ, Adame A, Masliah E. Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects. Neuroscience. 2014;275:352–64.
32.
go back to reference Santos SD, Lambertsen KL, Clausen BH, et al. CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem. 2010;115:1434–44. Santos SD, Lambertsen KL, Clausen BH, et al. CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem. 2010;115:1434–44.
33.
go back to reference Gomes JR, Nogueira RS, Vieira M, et al. Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia. Cell Death Differ. 2016;23:1749–64. Gomes JR, Nogueira RS, Vieira M, et al. Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia. Cell Death Differ. 2016;23:1749–64.
34.
go back to reference Gao C, Zhang B, Zhang W, Pu S, Yin J, Gao Q. Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction. Clin Exp Med. 2011;11:49–544. Gao C, Zhang B, Zhang W, Pu S, Yin J, Gao Q. Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction. Clin Exp Med. 2011;11:49–544.
35.
go back to reference Hornstrup LS, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Arterioscler Thromb Vasc Biol. 2013;33:1441–7. Hornstrup LS, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Arterioscler Thromb Vasc Biol. 2013;33:1441–7.
36.
go back to reference Maetzler W, Tian Y, Baur SM, et al. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS ONE. 2012;7:e48042. Maetzler W, Tian Y, Baur SM, et al. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS ONE. 2012;7:e48042.
37.
go back to reference Miller-Thomas MM, Sipe AL, Benzinger TL, McConathy J, Connolly S, Schwetye KE. Multimodality review of amyloid-related diseases of the central nervous system. Radiographics. 2016;36:1147–63. Miller-Thomas MM, Sipe AL, Benzinger TL, McConathy J, Connolly S, Schwetye KE. Multimodality review of amyloid-related diseases of the central nervous system. Radiographics. 2016;36:1147–63.
38.
go back to reference Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994;91:8368–72. Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994;91:8368–72.
39.
go back to reference Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22:7380–8. Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22:7380–8.
40.
go back to reference Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci. 2004;24:7707–17. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci. 2004;24:7707–17.
41.
go back to reference Buxbaum JN, Ye Z, Reixach N, et al. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A-beta toxicity. Proc Natl Acad Sci USA. 2008;105:2681–6. Buxbaum JN, Ye Z, Reixach N, et al. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A-beta toxicity. Proc Natl Acad Sci USA. 2008;105:2681–6.
42.
go back to reference Costa R, Goncalves A, Saraiva MJ, Cardoso I. Transthyretin binding to A-Beta peptide–impact on A-Beta fibrillogenesis and toxicity. FEBS Lett. 2008;582:936–42. Costa R, Goncalves A, Saraiva MJ, Cardoso I. Transthyretin binding to A-Beta peptide–impact on A-Beta fibrillogenesis and toxicity. FEBS Lett. 2008;582:936–42.
43.
go back to reference Silva CS, Eira J, Ribeiro CA, et al. Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis. Neurobiol Aging. 2017;59:10–4. Silva CS, Eira J, Ribeiro CA, et al. Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis. Neurobiol Aging. 2017;59:10–4.
44.
go back to reference Alemi M, Silva SC, Santana I, Cardoso I. Transthyretin stability is critical in assisting beta amyloid clearance- relevance of transthyretin stabilization in Alzheimer's disease. CNS Neurosci Ther. 2017;23:605–19. Alemi M, Silva SC, Santana I, Cardoso I. Transthyretin stability is critical in assisting beta amyloid clearance- relevance of transthyretin stabilization in Alzheimer's disease. CNS Neurosci Ther. 2017;23:605–19.
45.
go back to reference Li X, Zhang X, Ladiwala AR, et al. Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. J Neurosci. 2013;33:19423–33. Li X, Zhang X, Ladiwala AR, et al. Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. J Neurosci. 2013;33:19423–33.
46.
go back to reference Cascella R, Conti S, Mannini B, et al. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim Biophys Acta. 2013;1832:2302–14. Cascella R, Conti S, Mannini B, et al. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim Biophys Acta. 2013;1832:2302–14.
Metadata
Title
A Narrative Review of the Role of Transthyretin in Health and Disease
Authors
Marcia Almeida Liz
Teresa Coelho
Vittorio Bellotti
Maria Isabel Fernandez-Arias
Pablo Mallaina
Laura Obici
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 2/2020
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-020-00217-0

Other articles of this Issue 2/2020

Neurology and Therapy 2/2020 Go to the issue